Paliperidone
SGA • Last reviewed 2025-09-23
Brands: Invega
Sources updated 2025 • 1 references
General Information
Indicated for: Schizophrenia; schizoaffective disorder. Second‑generation antipsychotic (SGA) Also available as a long‑acting injectable (see LAI section below).
Dosage & Administration
Typical dose range: 3–12 mg/day (ER)
Indications (label)
Schizophrenia; schizoaffective disorder.
View labelExact
Mechanism (brief)
D2 and 5-HT2A antagonism; active metabolite of risperidone.
Metabolism & Half‑life
- Metabolism: Minimally hepatic; largely renal excretion unchanged.
- Half‑life: ~23 h (ER).
Therapeutic Drug Monitoring (TDM)
Recommended: No
Long‑acting injectable (LAI)
Paliperidone palmitate (PP1M/PP3M/PP6M)
- Interval
- Monthly / q3mo / q6mo
- Oral overlap
- None after loading sequence
- Site
- Deltoid (initiation) or gluteal
References
- Paliperidone labelExact (2025)
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. — CNS Drugs (2021)
- 6‑month paliperidone palmitate (PP6M): review — Review (2021)
- Paliperidone palmitate long‑acting injection: efficacy and safety (review) — Review (2018)
- Paliperidone palmitate vs oral antipsychotics: comparative effectiveness — Observational (2017)